Blood:plasma concentration ratio of paclitaxel in the absence and presence of various concentrations of CrEL, castor oil, and HPLC fractions of CrELa
| Compound added (%) | Blood:plasma ratio | Percentage change vs. control (%) | Pb |
|---|---|---|---|
| None | 1.07 ± 0.004 | ||
| CrEL (0.01) | 1.09 ± 0.009 | +1.83 | 0.387 |
| CrEL (0.05) | 0.990 ± 0.015 | −9.35 | 0.012 |
| CrEL (0.10) | 0.901 ± 0.017 | −15.8 | 0.003 |
| CrEL (0.50) | 0.690 ± 0.005 | −35.5 | <0.0001 |
| CrEL (1.0) | 0.625 ± 0.008 | −41.6 | <0.0001 |
| Castor oil (0.50) | 1.23 ± 0.171 | +13.0 | 0.061 |
| CrEL fraction 1 (0.50) | 1.06 ± 0.008 | −0.94 | 0.520 |
| CrEL fraction 2 (0.50) | 0.926 ± 0.018 | −13.5 | 0.043 |
| CrEL fraction 3 (0.50) | 0.763 ± 0.055 | −28.7 | 0.010 |
| CrEL fraction 4 (0.50) | 0.645 ± 0.051 | −39.7 | 0.003 |
| CrEL fraction 5 (0.50) | 0.943 ± 0.039 | −11.9 | 0.103 |
a Paclitaxel was used at an initial concentration of 1 μg/ml and incubated in whole blood for 15 min at 37°C before fractionation and HPLC analysis. Ratio data are presented as mean values ± SD of (at least) triplicate measurements.
b Probability value versus control (unpaired two-sided Student’s t test).